Implementing Next-Generation Sequencing for Precision Oncology Testing
Title: Implementing Next-Generation Sequencing for Precision Oncology Testing
Date: Thursday, November 29
Time: 1:00 p.m. ET
Presenter: Brian Piening, PhD
Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.
Rapidly Testing for Biomarkers
According to a recent study by the Tufts Center for the Study of Drug Development, the majority of cancer treatments in development have an associated genomic biomarker — a trend that’s expected to increase in the coming years. With this evolution in the clinical oncology landscape, academic medical centers and hospital systems alike have adopted diagnostic precision medicine tools like next-generation sequencing (NGS), which enables labs to rapidly and simultaneously test multiple genomic biomarkers from just a few nanograms of precious tumor tissue. As the number of clinically significant biomarkers continues to expand, this testing will continue to play a critical role in cancer diagnosis and treatment.
In this P.A.C.E.-accredited Fisher Healthcare webinar, Brian Piening, PhD, will highlight the clinical and economic considerations for implementing an NGS-based personalized medicine program and discuss case studies that demonstrate the benefits of determining the genomic profiles of a variety of cancer types.
This webinar will help you:
- Evaluate the process of deciding whether to implement NGS in a clinical pathology lab
- Describe the available testing strategies and chemistries
- Review case studies in which NGS is uniquely suited to provide novel clinical insights
This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.
Brian Piening, PhD
Dr. Piening is currently the Associate Director of the Providence St. Joseph Health (PSJH) Molecular Genomics Laboratory and Assistant Member and head of the Tumor Immunogenomics Laboratory at the Earle A. Chiles Research Institute and Providence Cancer Center in Portland, Oregon. He focuses on expanding access to clinical genomics testing to patients in need across one of the largest healthcare systems in the United States. His research laboratory focuses on using novel multi-omic technologies to better characterize the diversity of biological responses to cancer immunotherapies.
Dr. Piening completed his training in Molecular and Cellular Biology at the University of Washington and Fred Hutchinson Cancer Research Center, and his postdoctoral training in the Department of Genetics at Stanford University.